Dermatology Clinical Trials and Research: How Patients Can Participate

Dermatology clinical trials test new treatments, devices, and diagnostic tools for skin conditions ranging from acne and eczema to melanoma and rare genodermatoses. Understanding how trials are structured, regulated, and accessed helps patients and clinicians evaluate whether participation is appropriate for a given clinical situation. This page covers the phases of dermatology research, the regulatory framework governing participant safety, common trial scenarios across skin disease categories, and the criteria that distinguish eligible from ineligible candidates.

Definition and Scope

A clinical trial is a prospective research study that assigns human participants to one or more interventions to evaluate health-related outcomes. The U.S. Food and Drug Administration (FDA) regulates clinical trials for drugs, biologics, and devices under 21 CFR Parts 312 (Investigational New Drug applications) and 812 (Investigational Device Exemptions). In dermatology specifically, trials span four domains: pharmacological (topical agents, systemic drugs, biologics), device-based (laser systems, phototherapy equipment), surgical (wound closure techniques, Mohs margins), and behavioral (sun protection interventions, patient education protocols).

The National Institutes of Health (NIH) ClinicalTrials.gov database registers thousands of active dermatology studies at any given time — as of the 2023 fiscal year, the database contained more than 490,000 registered studies worldwide, with dermatology-specific trials comprising a substantial subset across psoriasis, atopic dermatitis, skin cancer, and rare skin disorders. Registration on ClinicalTrials.gov is mandatory for applicable clinical trials under the FDA Amendments Act of 2007 (FDAAA 801).

The regulatory context for dermatology shapes what trial designs are permissible, which endpoints qualify for regulatory acceptance, and how adverse events must be reported — all factors patients encounter directly during the consent and monitoring phases.

How It Works

Phases of a Clinical Trial

Dermatology drug and biologic trials follow the FDA's standard four-phase model:

  1. Phase I — First-in-human testing, typically 20–80 participants, focused on safety, tolerability, and pharmacokinetics. Dose-finding is the primary objective.
  2. Phase II — Expanded safety and preliminary efficacy evaluation in 100–300 participants with the target condition (e.g., moderate-to-severe plaque psoriasis). Endpoints may include validated instruments such as the Psoriasis Area and Severity Index (PASI) or the Eczema Area and Severity Index (EASI).
  3. Phase III — Pivotal randomized controlled trials in 300–3,000 or more participants. These trials generate the efficacy and safety data submitted in a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA.
  4. Phase IV — Post-marketing surveillance studies required by the FDA after approval to monitor long-term safety in broader populations.

All trials involving human participants must obtain written informed consent under 45 CFR Part 46 (the Common Rule), administered by the Department of Health and Human Services (HHS). An Institutional Review Board (IRB) — an independent ethics committee — must review and approve each trial protocol before enrollment begins. The IRB evaluates risk-to-benefit ratio, consent document clarity, and participant privacy protections under the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule (45 CFR Parts 160 and 164).

Trials are funded by sponsors — pharmaceutical companies, the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), or academic medical centers — and conducted at investigator sites such as university dermatology departments and private practice research centers. A principal investigator (PI), typically a board-certified dermatologist, supervises participant safety and data integrity at each site.

Common Scenarios

Dermatology trials cluster around three high-burden disease categories:

Inflammatory skin disease — Atopic dermatitis and psoriasis together account for a disproportionate share of dermatology trial activity. Trials in this category frequently evaluate biologics targeting interleukin pathways (IL-4, IL-13, IL-17, IL-23). Participants in these trials typically have moderate-to-severe disease that has not responded adequately to at least one conventional systemic agent such as methotrexate or cyclosporine. Detailed background on biologics for dermatology provides context on the mechanism classes under active investigation.

Skin cancer — Trials for melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) span adjuvant therapy, neoadjuvant immunotherapy, combination checkpoint inhibitor protocols, and novel topical chemoprevention agents. The NCI's Cancer Therapy Evaluation Program (CTEP) sponsors a significant portion of oncology-focused dermatology trials.

Rare and orphan skin disorders — Conditions including epidermolysis bullosa, ichthyosis, and pemphigus vulgaris are targets of FDA-designated orphan drug trials. The Orphan Drug Act (Public Law 97-414) provides regulatory incentives to sponsors developing treatments for diseases affecting fewer than 200,000 persons in the United States.

Decision Boundaries

Not every patient with a skin condition is an appropriate trial candidate. Eligibility is governed by written inclusion and exclusion criteria in each protocol, reviewed by the FDA and IRB before enrollment.

Inclusion criteria commonly specify: confirmed diagnosis (often by skin biopsy), disease severity thresholds (e.g., PASI ≥ 12 for moderate-to-severe psoriasis trials), age range, and adequate organ function if systemic agents are involved.

Exclusion criteria typically disqualify participants with: pregnancy or breastfeeding status, active immunosuppressive therapy that would confound results, prior exposure to the investigational agent, significant comorbidities (hepatic impairment, active infections, prior malignancy within 5 years), or participation in another interventional trial within a defined washout window.

A comparison of sponsored industry trials vs. federally funded trials reveals meaningful structural differences: industry trials often have narrower eligibility windows to optimize regulatory signal clarity, while NIH-funded trials, such as those coordinated through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), more frequently enroll participants with comorbidities or underrepresented demographics to generate generalizable population data.

Patients exploring participation can search active studies by condition and ZIP code through ClinicalTrials.gov. The National Dermatology Authority home resource index provides reference context on condition classification that may assist patients in identifying the correct disease category when searching trial registries. Broader patient rights during dermatology care — including trial withdrawal rights — are addressed in the patient rights in dermatology care reference.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)